

# 1 Seroepidemiology of COVID-19 in pregnant 2 women and their infants in Uganda and Malawi 3 across multiple waves 2020-2022 4

5 Lauren Hookham<sup>1,2\*</sup>, Liberty Cantrell<sup>2</sup>, Stephen Cose<sup>3,4</sup>, Bridget Freyne<sup>5,6</sup>, Luis Gadama<sup>7</sup>,  
6 Esther Imede<sup>4</sup>, Kondwani Kawaza<sup>7</sup>, Samantha Lissauer<sup>5,6</sup>, Phillipa Musoke<sup>8</sup>, Vicki  
7 Nankabirwa<sup>9</sup>, Musa Sekikubo<sup>10</sup>, Halvor Sommerfelt<sup>11,12</sup>, Merryn Voysey<sup>2</sup>, The periCOVID  
8 Consortium<sup>^</sup>, Kirsty Le Doare<sup>1,13</sup>,

9  
10 1 Institute for Infection and Immunity, St George's, University of London, London, UK

11 2 Oxford Vaccine Group, Department of Paediatrics, University of Oxford

12 3 London School of Hygiene & Tropical Medicine

13 4 MRC/UVRI and LSHTM Uganda Research Unit

14 5 Malawi Liverpool Wellcome Trust

15 6 Institute of Infection, Veterinary and Ecological Science, University of Liverpool

16 7 Kamuzu University of Health Sciences: University of Malawi College of Medicine

17 8 Department of Paediatrics and Child Health, Makerere University

18 9 Department of Epidemiology & Biostatistics, School of Public Health, Makerere University

19 10 Department of Obstetrics & Gynaecology Makerere University

20 11 Centre for Intervention Science in Maternal and Child Health, Department of Global

21 Public Health and Primary Care, University of Bergen

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

22 12 Norwegian Institute of Public Health.

23 13 Makerere University, John's Hopkins University, Uganda

24

25 \* Corresponding author

26 E-mail: [lhookham@sgul.ac.uk](mailto:lhookham@sgul.ac.uk)

27 ^Membership of the periCOVID Consortium is provided in the Acknowledgments.

28

29

## 30 **Abstract**

31 Data on SARS-CoV-2 infection in pregnancy and infancy has accumulated throughout the  
32 course of the pandemic. However, limited information is available from countries in sub-  
33 Saharan Africa (SSA). Evidence regarding asymptomatic SARS-CoV-2 infection and adverse  
34 birth outcomes are also scarce in these countries. The pregnant woman and infant COVID in  
35 Africa study (PeriCOVID Africa) is a South-South-North partnership involving hospitals and  
36 health centres in five countries: Malawi, Uganda, Mozambique, The Gambia, and Kenya. The  
37 study leveraged data from three ongoing prospective cohort studies: Preparing for Group B  
38 Streptococcal Vaccines (GBS PREPARE), SARS-CoV-2 infection and COVID-19 in women and  
39 their infants in Kampala and Mukono (COMAC) and Pregnancy Care Integrating Translational  
40 Science Everywhere (PRECISE). In this paper we describe the seroepidemiology of SARS-  
41 CoV-2 infection in pregnant women enrolled in sites in Uganda and Malawi, and the impact  
42 of SARS-CoV-2 infection on pregnancy and infant outcomes.

43 The PeriCOVID study is a prospective mother-infant cohort study that recruited pregnant  
44 women at any gestation antenatally or on the day of delivery. A nasopharyngeal swab was  
45 taken from mothers at enrolment for RT-PCR confirmation of SARS-CoV-2 infection, and  
46 maternal and cord blood samples were tested for SARS-CoV-2 antibodies using Wantai and  
47 Euroimmune ELISA. The primary outcome was seroprevalence of SARS-CoV-2 antibodies in  
48 maternal blood, reported as the proportion of seropositive women by study site and wave  
49 of COVID-19 within each country. Placental transfer of antibodies was described using the  
50 geometric mean ratio (GMR). We also estimated the proportion of asymptomatic or  
51 subclinical COVID-19 infections in pregnant women using serological testing and collected

52 adverse pregnancy and infancy outcomes (e.g. still-birth, prematurity, maternal or infant  
53 death).

54 In total, 1379 women were enrolled, giving birth to 1387 infants. Overall, 63% of pregnant  
55 women had a SARS-CoV-2 positive serology. Over subsequent waves (delta and omicron) , in  
56 the absence of vaccination, seropositivity rose from 20% to over 80%. The placental transfer  
57 GMR was 1.7, indicating active placental transfer of anti-spike IgG. There was no association  
58 between SARS-CoV-2 antibody positivity and adverse pregnancy or infancy outcomes.

59 This study describes the increasing prevalence of SARS CoV-2 antibodies in pregnant woman  
60 in Uganda and Malawi across waves of SARS-CoV-2 infection. Our study adds to existing  
61 evidence that suggests under-reporting of infection if based solely on cases with clinical  
62 disease, or a positive RT-PCR for SARS-CoV-2, as most of the women in our study had  
63 asymptomatic infections and did not seek medical care. This has implications for screening  
64 in subsequent outbreaks and pandemics where protection of pregnant women and effect of  
65 infection in pregnancy on the infant are unknown.

66

## 67 **Introduction**

68 The initial predictions of the impact of SARS-CoV-2 in sub-Saharan Africa suggested high  
69 case numbers and fatalities (1), yet there is evidence to suggest that the pandemic evolved  
70 differently in Africa than in other regions (2, 3). Several factors have been proposed to  
71 explain the relatively low frequency of severe SARS-CoV-2 illness, including a younger  
72 population, a lack of long-term care facilities and reduced population density (4-7).  
73 However, limited testing capacity and weak reporting structures in many sub-Saharan  
74 African countries may also result in under-reporting, leading to an underestimation of the  
75 true risk of serious SARS-CoV-2 infection (3). Infection in pregnancy, even if asymptomatic or  
76 mild, may have long-term impacts for a pregnant woman or impair the neurodevelopment  
77 of her child, a risk which is well established for viral infections such as Zika virus or  
78 cytomegalovirus (8). Data on the impact of SARS-CoV-2 infection in pregnancy on  
79 neurodevelopmental outcomes is emerging (9, 10). Evidence regarding asymptomatic SARS-  
80 CoV-2 infection and adverse birth outcomes is limited and the long-term effects of the  
81 pandemic on infant health remain poorly understood (11).

82

83 Serological surveillance is a useful means of estimating population-level immunity against  
84 infectious diseases using cross-sectional studies of antibody prevalence (12). In the case of  
85 SARS-CoV-2, serological surveys are helpful in estimating the number of people who have  
86 been exposed to SARS-CoV-2, whether they were symptomatic or not to better clarify the  
87 dynamics of exposure during the different epidemic waves as vaccines were rolled out (13).  
88 For example, seroprevalence surveys conducted across Kenya, South Africa and Malawi

89 have all reported community transmission, which is several times higher than that detected  
90 by national virological surveillance programmes (14-16).

91

92 Seroprevalence studies in pregnancy enables insights into the real magnitude of exposure to  
93 SARS-CoV-2 infections and the extent of under-reporting of SARS-CoV-2 cases. Information  
94 on seroprevalence in pregnancy, placental antibody transfer and antibody half-life also offer  
95 the possibility to approximate the number of mother-infant dyads who could potentially  
96 exhibit immunological protection against subsequent infections, especially with low vaccine  
97 coverage in many low-resource settings (LRS). Finally, seroprevalence studies can also  
98 provide insight into the relationship between infection and vaccination, symptoms, and  
99 antibody responses to assist with future screening and prevention policies in pregnancy.

100

101 To address these specific gaps, we investigated the seroprevalence and the associations of  
102 different factors on seropositivity to the SARS-CoV-2 virus among pregnant women and their  
103 infants in Uganda and Malawi. This was performed during consecutive SARS-CoV-2 waves.

104

## 105 **Methods**

### 106 **Study design and participants**

107 PeriCOVID Africa is a multi-site prospective mother-infant cohort study using an adapted  
108 WHO UNITY protocol (17), whereby women were categorised into two categories  
109 dependent on serological testing using the Wantai total antibody assay as exposed (positive  
110 serology) or unexposed (negative serology) to SARS-CoV-2. Women were additionally  
111 screened for symptoms, using the WHO definition for probable COVID-19 disease at the

112 time of study participation (18). We defined symptomatic COVID-19 infection according to  
113 the WHO definitions of probable COVID-19 illness (18) and asymptomatic infection as  
114 seropositive or PCR positive at enrolment in the absence of reported symptoms. Unexposed  
115 women were those with no reported symptoms consistent with SARS-CoV-2 infection and  
116 negative serology.

117

### 118 ***Recruitment***

119 Each study adapted the WHO UNITY protocol according to local needs and capacity  
120 considerations. Women were recruited into the study either during an antenatal visit, or  
121 during labour at seven study clinics and hospitals in Uganda and Malawi. In all studies,  
122 gestational age at enrolment was estimated by date of last menstrual period and fundal  
123 height. Additionally, in periCOVID Uganda and periCOVID Malawi Ballard scores were  
124 calculated at birth. Individual study recruitment, sampling and follow up are shown in Table  
125 1. The first participant was recruited 1<sup>st</sup> February 2021. Final participant follow and sampling  
126 was concluded by 31<sup>st</sup> January 2022.

127

128 **Table 1. Recruitment, sampling and follow-up by study site.**

129

Study Site	Enrolment timing	Study period	Inclusion Criteria	Exclusion Criteria	Sampling at enrolment	Follow up
All sites			Willingness to provide informed consent		Maternal and Cord blood	6 week follow up
periCOVID Uganda	Antenatal clinic or delivery	February 2021 – January 2022	<p>Pregnant women (including emancipated minors aged over 14 years) at any gestation including the day of delivery</p> <p>Planning to deliver at one of the designated study sites and willing to stay in the area for the first six weeks of their baby's life</p> <p>Willing to attend a follow up visit at six weeks postpartum</p>	No exclusion criteria	Maternal nasopharyngeal swab*	<p><b>For COVID-19 Cases only*. Maternal:</b> nasopharyngeal maternal blood sample (5ml serum),</p> <p><b>Infant:</b> nasal swab, blood sample (2-5ml) or dried blood spot,</p>
COMAC	Delivery	August 2021 – January 2022	<ul style="list-style-type: none"> <li>- low risk of infection with tuberculosis in the household</li> <li>-mother of legal age (including if emancipated minor) for participation</li> <li>-mother residing within the study area, not intending to move out</li> </ul>	<ul style="list-style-type: none"> <li>- Baby weighs less than 2kg at birth</li> <li>- Baby requires hospital admission for severe illness at birth</li> <li>- Serious congenital malformation(s)</li> <li>- severely ill mother on the day of giving birth whose condition(s)</li> </ul>	Nil additional	<p><b>Maternal</b> blood test at 14 weeks.</p> <p>Nasopharyngeal swab at 6 weeks and 14 weeks. <b>Infant:</b> blood test at 14 weeks.</p> <p>Nasopharyngeal swab at 6 weeks and 14 weeks</p>



			<p>of the area in the next 4 months and is likely to be traceable for up to 12 months.</p> <ul style="list-style-type: none"> <li>- HIV-1 positive women should be receiving the necessary antiretroviral treatment and prophylaxis (Ugandan Option B+ guidelines)</li> </ul> <p>HIV-exposed babies receives peri exposure prophylaxis (Ugandan Option B+ guidelines)</p>	<p>require(s) hospitalization</p> <p>-</p>		
Malawi	Delivery	March 2021 – January 2022	<p>All women presenting to QECH in labour with an estimated gestation of 28 weeks or greater who</p> <ul style="list-style-type: none"> <li>- Are willing to attend a follow up visit at 6 weeks postpartum</li> </ul>	No exclusion criteria.	Nil additional	<p><b>For COVID-19 cases only. Maternal</b></p> <p>*blood, rectal swab, breastmilk. <b>Infant*:</b></p> <p>blood</p>

131

## 132 ***COVID-19 testing***

133 All women at all study sites were screened for COVID-19 symptoms using a standardised  
134 data collection form with questions including a recent history of fever, cough, anosmia and  
135 ageusia and contact with a known SARS-Cov-2 case. Information on COVID-19 illness  
136 symptoms was collected at enrolment for the 14 days prior to enrolment in PeriCOVID  
137 Uganda and Malawi, and in the 28 days prior to enrolment in COMAC Uganda. Women  
138 enrolled in PeriCOVID Uganda had a nasal swab taken at enrolment to test for SARS-CoV-2  
139 by PCR. In Malawi throat swabs were taken if the clinical syndrome was suggestive of a  
140 probable COVID-19 illness as defined by the WHO (18).

## 141 ***Blood sampling***

142 Sampling at all sites for antibodies to SARS-COV-2 included at least a maternal venous and  
143 paired cord blood sample (see Table 1 for sampling schedule at each site).

## 144 ***Data collection***

145 Each site (KNRH, Kawaala, Kitebi or Mukono General Hospital in Kampala, Uganda and QECH  
146 in Blantyre, Malawi) used a study questionnaire which was completed by research staff to  
147 capture information from study participants and then uploaded to a central RedCAP  
148 database. This included data on maternal age, significant past medical history, HIV and  
149 socioeconomic status; onset and duration of signs and symptoms of SARS-CoV-2 illness if  
150 present, and self-reporting of prior SARS-CoV-2 illness; gestational age at enrolment, parity,  
151 number of foetuses (if known before delivery), co-infection with malaria, vaccinations  
152 received in pregnancy including the SARS-CoV-2 vaccines; gestational age at delivery,  
153 delivery method, intrapartum and postpartum complications such as pre-term birth,

154 stillbirth, abortion, and maternal death; neonatal outcomes including evidence of COVID-19  
155 illness, Neonatal Intensive Care Unit (NICU) admission, low birth weight and neonatal death;  
156 infant health status

157

## 158 **Laboratory methods**

159 As per FIND guidelines at the time of the study protocol development (19), we used three  
160 different SARS-CoV-2 specific antibody assays that targeted either the receptor binding  
161 domain (RBD; total antibody), the spike protein (anti-S, total antibody) or nuclear capsid  
162 (anti-NCP, IgG). We performed in-house specificity and sensitivity testing, respectively, using  
163 100 pre-COVID19 (pre-2019) samples selected by month for seasonality assessment and 20  
164 PCR positive samples (19) to perform assay validation. We also examined potential cross-  
165 reactivity in our assay from malaria-specific antibodies using 74 women who tested positive  
166 to malaria (antibody positive by rapid diagnostic test (RDT) from pre-COVID samples and 15  
167 SARS-COV-2 PCR positive samples in women who did not have malaria (negative RDT) during  
168 the COVID-19 pandemic. Results can be seen in Supplementary Table S1.

169

## 170 ***Laboratory analysis***

171 Laboratory testing for SARS-COV-2 antibodies was performed at the MRC/UVRI and LSHTM  
172 Uganda Research Unit or the Malawi Liverpool Wellcome facilities using the Wantai SARS-  
173 CoV-2 total antibody ELISA kit (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, Beijing,  
174 China). The manufacturer-reported assay sensitivity is 94.4%, with a specificity of 100%. All  
175 specimens that tested positive for Wantai were tested using Euroimmun Anti-SARS-CoV-2  
176 NCP/S ELISA (IgG) (Euroimmun, Lübeck, Germany) kits for the detection of IgG antibodies to

177 SARS-CoV-2 nucleocapsid and spike (S1 and S2) proteins, respectively. Euroimmun Anti-SARS-  
178 CoV-2 NCP/S ELISA (IgG) is a semi-quantitative immunoassay with a reported sensitivity of  
179 94.6% and specificity of 99.8% in samples collected at least 10 days after confirmed SARS-  
180 CoV-2 infection. A sample was considered positive if the Wantai test was positive. Results  
181 which were reported as borderline on the Euroimmune assay were considered as negative  
182 for the purpose of our analysis. Due to variable specificity of the Euroimmune assay, we report  
183 Wantai results for all outcomes as per manufacturer's instructions.

184 As the Wantai ELISA is a qualitative test, WHO standards for NCP and S proteins were run on  
185 all assays. The stock concentration for NCP and S proteins was 123µg/ml and 1000µg/ml,  
186 respectively. The working concentration for both NCP and S proteins was 2 µg/ml. The  
187 calibration curve was created using WHO International standard for anti-SARS-CoV-2  
188 immunoglobulin (NIBSC 20/136) using a 12-well dilution series created in 1.75-fold steps,  
189 starting at 1:200 and this series was used to generate the curve. All laboratory testing in  
190 Uganda for SARS-CoV-2 antibodies was performed using the ETI-MAX 3000 (Diasorin,  
191 Saluggia, Italy).

192

## 193 **Data Analysis**

194 Although there was no predefined sample size, we aimed to obtain samples from at least  
195 1000 women and infants across all sites. The sero-epidemiological analyses were carried out  
196 using all participants with enrolment blood sample results available for analysis. The  
197 proportion of seropositive results was calculated for the individual waves of SARS-CoV-2  
198 within each country. This was done for maternal blood samples to estimate the  
199 seroprevalence of SARS-CoV-2 among pregnant women, and for cord blood samples to

200 estimate the seroprevalence of SARS-CoV-2 antibodies in infants. The dates used to define  
201 the SARS-COV-2 waves in each country are given in Table S2 and were taken from Our World  
202 in Data (20) . Waves were defined by taking the nadir between each peak for the start and  
203 end dates of each wave. Confidence intervals for prevalence estimates were computed  
204 using the Clopper-Pearson (Binomial Exact) method.

205

206 The geometric mean concentration (GMC) and 95% confidence intervals (CI) of anti-S and  
207 anti-NCP antibodies measured on the Euroimmune assay were calculated for mother-infant  
208 pairs. To study the rate of placental transfer of SARS-CoV-2 antibodies, the geometric mean  
209 ratio (GMR) of infant to maternal antibodies was calculated.

210

211 The proportion of participants with a symptomatic or asymptomatic infection was  
212 calculated for women who were seropositive at enrolment and for those who had a positive  
213 RT-PCR test at enrolment.

214

215 The impact of infection on key pregnancy and neonatal outcomes was modelled for women  
216 and infants in PeriCOVID Malawi and Uganda log-binomial generalised linear models (GLM)  
217 which were adjusted for country. Models were constructed for maternal death, infant  
218 death, combined adverse pregnancy outcome (at least one of maternal death, abortion,  
219 premature labour or stillbirth), and the combined adverse neonatal outcome (at least one of  
220 neonatal/infant death, prematurity, low birth weight, NICU admission after birth, or birth  
221 asphyxia). Relative risks were presented with 95% confidence intervals for all models  
222 reaching convergence. Results were not presented for adverse outcomes with fewer than 5  
223 events.

224

225 Statistical analyses were carried out using R version 4.2.1. No significance tests were  
226 conducted.

227

## 228 **Ethical Considerations**

229 The study documents were reviewed and approved by the Ethics Committee of the relevant  
230 institutions: Uganda: Makerere University School of Medicine (SOMREC), Uganda National  
231 Council for Science and Technology (UNCST); Regional Committees for Medical and  
232 Research Ethics in Norway; Malawi: College of Medicine Research Ethics Committee  
233 (COMREC).

234

235

## 236 **Results**

237 In total, 1379 women were enrolled, giving birth to 1387 infants (Fig 1, Table 2). The mean  
238 age of all women was 26 years (SD 6) across the three sites. Most (n=1346, 98%)  
239 pregnancies were singleton. The HIV prevalence was 9% (n= 272). 371 women delivered  
240 outside of a study hospital and so no blood samples were available for analysis. Deliveries of  
241 1024 infants with cord blood samples occurred at study sites. Almost all were livebirths  
242 (n=1009/1024, 99%) and most (n=888/1024, 87%) were not admitted to the NICU after birth  
243 (Table 2). A total of 909/1379 (65.9%) women in periCOVID Uganda and periCOVID Malawi  
244 had a PCR result at enrolment available for analysis of which 68/909 (7.5%) women had  
245 positive PCR results for SARS-CoV-2. Amongst these women, 77.9% (n=53) had symptoms  
246 consistent with COVID-19 disease. The majority (88.7%, n=47/53) were in Malawi who were

247 performing RT-PCR testing only on symptomatic women. In periCOVID Uganda, where all  
248 women had a RT-PCR test at enrolment, 31.6% (n=6/19) of those with a positive RT-PCR test  
249 had symptoms suggestive of COVID-19 disease (Supplemental Table 3). Genotyping revealed  
250 all positive cases from Uganda to be of the delta variant.

251

252

253 **Fig 1. Study flow chart.** Study flow chart to show the number of women enrolled by study,  
254 with maternal serology available at enrolment (maternal result) and the infants with cord  
255 blood serology (cord blood result) available.

256

257

**Table 2. Demographics for women and infants in the study.**

258

<b>Characteristic of women enrolled</b>	<b>Overall, N = 1,379</b>	<b>PeriCOVID Malawi, N = 387</b>	<b>PeriCOVID Uganda, N = 836</b>	<b>COMAC Uganda, N = 156</b>
Age (years)	26 (6)	25 (7)	26 (6)	27 (5)
Missing	2	2	0	0
Number of fetuses				
Singleton	1,346 (98%)	371 (96%)	819 (98%)	156 (100%)
Twins	30 (2.2%)	14 (3.6%)	16 (1.9%)	0 (0%)
Triplets	1 (<0.1%)	0 (0%)	1 (0.1%)	0 (0%)
Missing	2	2	0	0
Highest level of education				
Graduate Education /Terminal Degree Completed.	23 (1.7%)	1 (0.3%)	20 (2.4%)	2 (1.3%)
No Formal Education	12 (0.9%)	5 (1.3%)	5 (0.6%)	2 (1.3%)
Other	2 (0.1%)	0 (0%)	2 (0.2%)	0 (0%)
Primary Education Completed	211 (15%)	98 (26%)	84 (10%)	29 (19%)
Secondary Education Completed	252 (18%)	129 (34%)	105 (13%)	18 (12%)



Some Primary Education	239 (17%)	126 (33%)	86 (10%)	27 (17%)
Some Secondary Education	509 (37%)	0 (0%)	432 (52%)	77 (49%)
University / College Completed	127 (9.2%)	25 (6.5%)	101 (12%)	1 (0.6%)
Missing	4	3	1	0
HIV				
No	1,107 (91%)	325 (84%)	782 (94%)	0 (NA%)
Yes	114 (9.3%)	60 (16%)	54 (6.5%)	0 (NA%)
Missing	158	2	0	156
<b>Characteristics of infants born and providing a cord blood sample</b>	<b>Overall, N = 1,024</b>	<b>PeriCOVID Malawi, N = 365</b>	<b>PeriCOVID Uganda, N = 503</b>	<b>COMAC Uganda, N = 156</b>
Status of infant at birth				
Livebirth	1,009 (99%)	357 (99%)	496 (99%)	156 (100%)*
Miscarriage	2 (0.2%)	1 (0.3%)	1 (0.2%)	0 (0%)
Stillbirth	10 (1.0%)	4 (1.1%)	6 (1.2%)	0 (0%)
Missing	3	3	0	0
Gestation at birth (weeks)	27, 44	27, 44	28, 44	Inf, -Inf
Missing	157	1	0	156

Sex				
Female	492 (48%)	164 (45%)	248 (49%)	80 (51%)
Male	531 (52%)	200 (55%)	255 (51%)	76 (49%)
Missing	1	1	0	0
Birth weight (grams)				
Mean (SD)	3,082 (540)	2,910 (573)	3,151 (504)	3,262 (458)
Range	600, 4,850	600, 4,500	1,200, 4,850	2,100, 4,700
Missing	8	2	6	0
Admitted to NICU after birth				
No	888 (87%)	264 (73%)	468 (93%)	156 (100%)*
Yes	133 (13%)	98 (27%)	35 (7.0%)	0 (0%)
Missing	3	3	0	0

259 \* COMAC Uganda only recruited infants who were born alive and not admitted to the NICU after birth

260

261

## 262 **Seropositivity in pregnant women and their infants**

263 Overall, 1371/1379 maternal samples (382 from Malawi and 989 from Uganda) and  
264 987/1024 cord blood samples (359 from Malawi and 628 from Uganda) were available for  
265 analysis (Table 3 and 4). There were 875 SARS-CoV-2 seropositive women in the study (257  
266 in Malawi, 618 in Uganda), of whom 791 (90.4%) were asymptomatic in the 14 days  
267 (periCOVID Uganda and Malawi) -28 days (COMAC) prior to enrolment. This corresponded in  
268 Malawi to 21 asymptomatic seropositive participants during the second wave, 134 during  
269 the third wave and 57 in the fourth wave. In Uganda, this corresponded to 92 in the first  
270 wave, 422 in the second wave and 65 in the third wave (Table 3).

271 There was an increase in seropositivity with each subsequent wave, and the majority (70-  
272 100%) of women with positive serology were asymptomatic in the 14 days prior to sampling.  
273 Fig 2 shows the monthly total antibody positivity rate for each site with the daily number of  
274 new cases per million in Uganda and Malawi. The concordance between maternal and cord  
275 samples was high (72-99%).

276

277 **Fig 2. Monthly sero-positivity by country in pregnant women.** Black line is the monthly  
278 proportion of results that were positive. Shaded in green is the proportion of Wantai  
279 positive samples that were also positive for anti-spike IgG in the Euroimmune assay. Blue  
280 line is the number of new cases per million in Malawi and Uganda, taken from Our World in  
281 Data.

282

283

284

285

286 Table 3 – Maternal results

	PeriCOVID Malawi			PeriCOVID Uganda		COMAC Uganda	
Characteristic	Wave 2, N = 51 N (%) (95% CI)	Wave 3, N = 229 N (%) (95% CI)	Wave 4, N = 107 N (%) (95% CI)	Wave 1, N = 194 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% CI)	Wave 3, N = 74 N (%) (95% CI)
Maternal blood sample							
Negative	24 (51%) (36%, 66%)	75 (33%) (27%, 39%)	26 (24%) (17%, 34%)	102 (53%) (45%, 60%)	240 (38%) (34%, 41%)	22 (27%) (18%, 38%)	7 (9.6%) (3.9%, 19%)
Positive	23 (49%) (34%, 64%)	153 (67%) (61%, 73%)	81 (76%) (66%, 83%)	92 (47%) (40%, 55%)	400 (62%) (59%, 66%)	60 (73%) (62%, 82%)	66 (90%) (81%, 96%)
Missing	4	1	0	0	2	0	1
Symptoms in those seropositive							
Asymptomatic	21 (91%) (72%, 99%)	134 (88%) (81%, 92%)	57 (70%) (59%, 80%)	92 (100%) (96%, 100%)	362 (91%) (87%, 93%)	60 (100%) (94%, 100%)	65 (98%) (92%, 100%)
Symptomatic	2 (8.7%) (1.1%, 28%)	19 (12%) (7.6%, 19%)	24 (30%) (20%, 41%)	0 (0%) (0.00%, 3.9%)	38 (9.5%) (6.8%, 13%)	0 (0%) (0.00%, 6.0%)	1 (1.5%) (0.04%, 8.2%)
Symptoms in those seronegative							
Asymptomatic	24 (100%) (86%, 100%)	61 (81%) (71%, 89%)	12 (46%) (27%, 67%)	101 (99%) (95%, 100%)	223 (93%) (89%, 96%)	22 (100%) (85%, 100%)	7 (100%) (59%, 100%)

	PeriCOVID Malawi			PeriCOVID Uganda		COMAC Uganda	
Characteristic	Wave 2, N = 51 N (%) (95% CI)	Wave 3, N = 229 N (%) (95% CI)	Wave 4, N = 107 N (%) (95% CI)	Wave 1, N = 194 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% CI)	Wave 3, N = 74 N (%) (95% CI)
Symptomatic	0 (0%) (0.00%, 14%)	14 (19%) (11%, 29%)	14 (54%) (33%, 73%)	1 (1.0%) (0.02%, 5.3%)	17 (7.1%) (4.2%, 11%)		

287

288 Table 4 – Cord blood serology

	PeriCOVID Malawi			PeriCOVID Uganda		COMAC Uganda	
Characteristic	Wave 2, N = 52 N (%) (95% CI)	Wave 3, N = 230 N (%) (95% CI)	Wave 4, N = 111 N (%) (95% CI)	Wave 1, N = 195 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% CI)	Wave 3, N = 74 N (%) (95% CI)
Concordance of maternal and cord blood samples							
Concordant	35 (80%) (65%, 90%)	194 (92%) (88%, 96%)	101 (96%) (91%, 99%)	79 (82%) (73%, 89%)	271 (72%) (67%, 76%)	81 (99%) (93%, 100%)	68 (96%) (88%, 99%)
Discordant	9 (20%) (9.8%, 35%)	16 (7.6%) (4.4%, 12%)	4 (3.8%) (1.0%, 9.5%)	17 (18%) (11%, 27%)	106 (28%) (24%, 33%)	1 (1.2%) (0.03%, 6.6%)	3 (4.2%) (0.88%, 12%)
Missing	8	20	6	99	265	0	3
Cord blood results with positive maternal blood result							
Negative	8 (40%) (19%, 64%)	14 (10%) (5.7%, 17%)	3 (3.8%) (0.78%, 11%)	8 (18%) (8.2%, 33%)	38 (16%) (12%, 21%)	0 (0%) (0.00%, 6.0%)	3 (4.7%) (0.98%, 13%)
Positive	12 (60%) (36%, 81%)	123 (90%) (83%, 94%)	77 (96%) (89%, 99%)	36 (82%) (67%, 92%)	198 (84%) (79%, 88%)	60 (100%) (94%, 100%)	61 (95%) (87%, 99%)
Missing	3	15	3	48	165	0	2
Cord blood result with negative maternal blood result							
Negative	23 (96%) (79%, 100%)	71 (97%) (90%, 100%)	24 (96%) (80%, 100%)	43 (83%) (70%, 92%)	73 (52%) (43%, 60%)	21 (95%) (77%, 100%)	7 (100%) (59%, 100%)

Characteristic	PeriCOVID Malawi			PeriCOVID Uganda		COMAC Uganda	
	Wave 2, N = 52 N (%) (95% CI)	Wave 3, N = 230 N (%) (95% CI)	Wave 4, N = 111 N (%) (95% CI)	Wave 1, N = 195 N (%) (95% CI)	Wave 2, N = 642 N (%) (95% CI)	Wave 2, N = 82 N (%) (95% CI)	Wave 3, N = 74 N (%) (95% CI)
Positive	1 (4.2%) (0.11%, 21%)	2 (2.7%) (0.33%, 9.5%)	1 (4.0%) (0.10%, 20%)	8 (15%) (6.9%, 28%)	68 (48%) (40%, 57%)	1 (4.5%) (0.12%, 23%)	0 (0%) (0.00%, 41%)
Missing	1	4	3	52*	98		

289 \* 1 cord blood sample in PeriCOVID Uganda was insufficient for analysis

290

291 **SARS-CoV-2 infection in pregnancy and key adverse pregnancy and**  
292 **neonatal outcomes**

293 1220/1224 mothers had serology results at enrolment available for analysis and were  
294 included in the analysis of Sars-CoV-2 infection and pregnancy outcomes. 79/1220 mothers  
295 experienced at least one adverse pregnancy outcome (maternal death N=4, abortion N=4,  
296 premature labour N=52, and stillbirth N=26) and there were 46 infant deaths (Supp Table 4  
297 and 5). Of the 79 adverse pregnancy outcomes, 34 (43%) mothers were sero-negative, and  
298 45 (57%) mothers were sero-positive, compared to 435 (38%) mothers who were sero-  
299 negative and 706 (62%) mothers who were sero-positive with no adverse pregnancy  
300 outcomes. There was no difference in pregnancy outcomes due to sero-positive SARS-CoV-  
301 2 status (Table 5). Due to the small numbers of outcomes, the impact of Sars-CoV-2  
302 infection on maternal death could not be modelled. There was also no difference in  
303 outcomes due to SARS-CoV-2 infection with and without symptoms in the 14 days  
304 (periCOVID Uganda and Malawi) -28 days (COMAC) prior to enrolment (Supp Table 6).



305

306 Table 5– Impact of infection (seropositivity) on key pregnancy and neonatal outcomes in Pericovid Malawi and Pericovid Uganda

	Number included in model	Number of events	Relative Risk	95% Confidence Interval
<b>Maternal death</b>				
Sero-Negative		1	—	—
Sero-Positive		3	—	—
<b>Infant death</b>				
Sero-Negative	471	20	—	—
Sero-Positive	752	26	0.81	0.46, 1.46
<b>Premature labour</b>				
Sero-Negative	476	20	—	—
Sero-Positive	758	32	0.97	0.57, 1.71
<b>Still birth</b>				
Sero-Negative	473	15	—	—
Sero-Positive	752	11	0.48	0.22, 1.03
<b>Abortion</b>				
Sero-Negative		0	—	—
Sero-Positive		4	—	—
<b>Combined adverse pregnancy outcome</b>				
Sero-Negative	463	34	—	—
Sero-Positive	742	45	0.81	0.53, 1.26
<b>Low birth weight</b>				
Sero-Negative	474	22	—	—
Sero-Positive	753	39	0.98	0.60, 1.65
<b>NICU admission</b>				
Sero-Negative	471	63	—	—

Sero-Positive	753	107	0.96	0.73, 1.28
<b>Combined adverse neonatal outcome</b>				
Sero-Negative	476	77	—	—
Sero-Positive	758	120	0.92	0.71, 1.19

307 Models are adjusted for country

308 There were 197 adverse infant outcomes (at least one of: infant/neonatal death,  
309 prematurity, low birth weight, NICU admission and birth asphyxia). There were 46 infant  
310 deaths, 26 (57%) from sero-positive and 20 (43%) from sero-negative women (Supp Table  
311 5). There was no difference in risk of infant death due to SARS-CoV-2 serology status in the  
312 mother (Table 5). 77 (39%) infants with adverse outcomes were born to women who were  
313 sero-negative and 120 (61%) sero-positive. The relative risk was 0.92 (95% CI 0.71, 1.19),  
314 providing no evidence of a difference in the risk of at least one adverse neonatal outcome  
315 due to serological status of the mother. There was also no evidence of a difference in  
316 neonatal outcome due to positive serological status with and without symptoms in the  
317 mother (Supp Tables 4 and 5).

318

### 319 **Placental transfer of SARS-CoV-2 antibodies in those with prior** 320 **infection and/or vaccination**

321 In PeriCOVID Uganda, 208/503 mother-infant pairs had anti-S IgG results available for  
322 analysis, corresponding to 27 and 181 during the first and second waves respectively. There  
323 was no difference between the maternal and cord blood anti-S IgG GMCs during the first  
324 wave. The GMR in the second wave was 1.7 (1.3, 2.3), indicating that anti-S IgG was higher  
325 in the cord blood than the maternal blood at enrolment. In comparison, in COMAC Uganda  
326 the GMR indicated no difference between the maternal and cord blood anti-S IgG for the 60  
327 mother-infant pairs enrolled during the second wave, or for the 59 enrolled during the third  
328 wave (Supp Table 7). The rate of placental transfer of anti-S IgG is plotted in Fig 3.

329

330 **Fig 3. Placental transfer of anti-s IgG in A) PeriCOVID Uganda and B) COMAC Uganda.**  
331 Geometric mean ratios (GMRs) of anti-spike IgG for each mother-infant pair with results  
332 available for analysis on the Euroimmune anti-spike IgG assay. Boxplots of the GMRs show  
333 no evidence of a difference in placental transfer in different waves of the pandemic.

334

335 There were 39 mother-infant pairs enrolled in PeriCOVID Uganda during the first wave with  
336 anti-NCP results, and 194 during the second wave. For both waves, there was no evidence

337 of a difference in the maternal and cord blood anti-NCP IgG results. In COMAC Uganda, 55  
338 and 43 mother-infant pairs enrolled during the second and third waves, respectively, had  
339 anti-NCP IgG results. The GMR in the second wave was 1.8 (1.1, 2.9), and in the third wave  
340 was 2.7 (1.7, 4.4), indicating that anti-NCP IgG was higher in cord blood samples than in the  
341 maternal blood (Supp Table 7). The rate of placental transfer of anti-NCP IgG is plotted in  
342 Fig 3 . There was no clear evidence of a difference in placental transfer of both anti-S and  
343 anti-NCP IgG during different waves (Fig 3 and Fig S1).

344

### 345 **Number of vaccinated women during pregnancy**

346 A total of 29 participants across all sites reported prior vaccination to SARS-CoV-2: 7 from  
347 Malawi, 1 from periCOVID Uganda and 21 from COMAC. Monthly numbers of positive  
348 results in COMAC Uganda by vaccination status can be seen in Fig S2.

349

## 350 **Discussion**

351 This study describes the increasing prevalence of SARS CoV-2 infection across 2 countries  
352 and 5 hospital sites in East and southern Africa, and across several COVID-19 waves. This  
353 increase in prevalence coincided with waves of delta and omicron infection within the  
354 countries, respectively. Our data indicates that the majority of cases were asymptomatic  
355 and adds to existing evidence that suggests under-reporting of infection if based solely on  
356 confirmed cases by PCR(4, 5, 21).

357

358 The high prevalence of poor maternal and child health outcomes in sub-Saharan Africa,  
359 combined with the known impact of SARS-CoV-2 illness in pregnancy from existing studies

360 outside of Africa (22-26), means that we need to better understand the direct effects of  
361 exposure to COVID-19 in pregnancy and outcome for the pregnant woman and her infant.  
362 The INTERCOVID study (27), which included 2 sites in West Africa (Nigeria and Ghana)  
363 showed that infection in pregnancy was associated with increased maternal and neonatal  
364 morbidity and mortality. The AFREHEALTH study of 1315 hospitalized pregnant and non-  
365 pregnant women with and without SARS-CoV-2 revealed an increased risk of ICU admission  
366 and in-hospital death amongst pregnant women with COVID-19 (28). Though we are unable  
367 to assess outcomes for symptomatic SARS-CoV-2 illness in our cohort due to low numbers  
368 our study does highlight that asymptomatic infection does not appear to be associated with  
369 death in the mother, or with worse neonatal outcomes in the first month of life. This is  
370 reassuring to parents and health care providers. Furthermore, in our study placental  
371 transfer of IgG increased during each subsequent wave. Previous studies earlier in the  
372 pandemic suggested reduced placental transfer of IgG in women with a positive SARS-CoV-2  
373 RT-PCR (29, 30). More research is needed to better understand placental transfer with  
374 different SARS-CoV-2 variants.

375

## 376 **Limitations**

377 Our study is limited by differences in methodology across sites, with sampling performed at  
378 different time points in pregnancy, despite efforts to adhere to the UNITY protocol. The  
379 uniform collection of cord blood across all sites however enables comparison across sites  
380 and strengthens our results. In PeriCOVID Uganda, a strict period of lockdown over the  
381 summer of 2021 with a ban on public transport made it challenging for participants to  
382 attend hospital for delivery, leading to a lower number of cord blood samples than

383 anticipated. Calls to participants by healthcare visitors were increased to ensure that  
384 women were aware that study staff were still working and could care for them during their  
385 delivery. We report our primary outcomes using the Wantai assay, but for placental  
386 antibody transfer, we report IgG using Euroimmune results. However, we identified cross-  
387 reactivity of antibodies against *Plasmodium falciparum* or other common cold coronaviruses  
388 (CCCs) as has been reported elsewhere in East Africa (21), meaning these results should be  
389 reviewed with caution. We had initially planned to use the Euroimmune anti-NCP assay to  
390 differentiate between infection and vaccination. However, the specificity of the assay  
391 precluded its use for this purpose. The Euroimmune anti-NCP assay has a lower sensitivity  
392 than other assays (31). Several studies have shown a low anti-NCP positivity after mild  
393 infections (32). As the pandemic progressed the chance of repeat SARS-CoV-2 infection  
394 increased, though these infections were generally milder (32). Anti-NCP antibodies in some  
395 studies have remained negative in individuals who were vaccinated against SARS-CoV-2 and  
396 who had an rt-PCR confirmed illness (32). A lower anti-NCP seropositivity later in the  
397 pandemic may therefore represent assay sensitivity and a lower anti-NCP immune response  
398 following mild or asymptomatic infection.

399

## 400 **Conclusion**

401 Data from Uganda and Malawi showed a seroprevalence of SARS-CoV-2 higher than the  
402 cases figures identified by other sources. In future pandemics and outbreaks,  
403 seroprevalence studies may be a more accurate measure in assessing the true prevalence of  
404 infection.

405

## 406 **Acknowledgments**

407 The periCOVID Consortium consists of:

408 Esperança Sevene<sup>1,2</sup>, Sónia Maculuve<sup>1</sup>, Anifa Valá<sup>1</sup>, Angela Koech<sup>3</sup>, Geoffrey Omuse<sup>4</sup>,

409 Marleen Temmerman<sup>3</sup>

- 410 1. Manhiça Health Research Center, Manhiça, Mozambique
- 411 2. Department of Physiological Science, Faculty of Medicine, Eduardo Mondlane University,  
412 Maputo, Mozambique
- 413 3. Centre of Excellence in Women and Child Health, Aga Khan University, Kenya
- 414 4. Department of Pathology, Aga Khan University, Kenya

415

416

417

418 We would also like to thank all study and laboratory staff who enabled recruitment, follow-

419 up, and study testing.

420

421

## 422 **References**

- 423 1. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong  
424 JN. COVID-19 in Africa: the spread and response. *Nature Medicine*. 2020;26(7):999-1003.
- 425 2. Abatan B, Agboghoroma O, Akemoke F, Antonio M, Awokola B, Bittaye M, et al.  
426 Intense and Mild First Epidemic Wave of Coronavirus Disease, The Gambia. *Emerging*  
427 *infectious diseases*. 2021;27(8):2064.
- 428 3. Martinez-Alvarez M, Jarde A, Usuf E, Brotherton H, Bittaye M, Samateh AL, et al.  
429 COVID-19 pandemic in west Africa. *The lancet global health*. 2020;8(5):e631-e2.
- 430 4. Adams J, MacKenzie MJ, Amegah AK, Ezech A, Gadanya MA, Omigbodun A, et al.  
431 The conundrum of low COVID-19 mortality burden in sub-Saharan Africa: myth or reality?  
432 *Global Health: Science and Practice*. 2021;9(3):433-43.
- 433 5. Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, et al.  
434 COVID-19 pandemic: is Africa different? *Journal of the National Medical Association*.  
435 2021;113(3):324-35.
- 436 6. Norton A, Gozalo ADLH, De Colombi NF, Aloba M, Asego JM, Al-Rawni Z, et al.  
437 The remaining unknowns: a mixed methods study of the current and global health research  
438 priorities for COVID-19. *BMJ Global Health*. 2020;5(7):e003306.
- 439 7. Tsinda EK, Mmbando GS. Recent updates on the possible reasons for the low  
440 incidence and morbidity of COVID-19 cases in Africa. *Bulletin of the National Research*  
441 *Centre*. 2021;45(1):1-8.
- 442 8. Sié A, Hanefeld J, Chaponda M, Chico RM, LeDoare K, Mayaud P, et al. Congenital  
443 malformations in sub-Saharan Africa—warnings of a silent epidemic? *The Lancet Infectious*  
444 *Diseases*. 2021;21(5):594-6.



- 445 9. Shah AV, Howell HB, Kazmi SH, Zaccario M, Sklamberg FE, Groth T, et al.  
446 Developmental screening of full-term infants at 16 to 18 months of age after in-utero  
447 exposure to maternal SARS-CoV-2 infection. *Journal of Perinatology*. 2023;43(5):659-63.
- 448 10. Edlow AG, Castro VM, Shook LL, Haneuse S, Kaimal AJ, Perlis RH. Sex-Specific  
449 Neurodevelopmental Outcomes Among Offspring of Mothers With SARS-CoV-2 Infection  
450 During Pregnancy. *JAMA Network Open*. 2023;6(3):e234415-e.
- 451 11. Emily RS, Erin O, Gargi Wable G, Kacey F, Fouzia F, Yalda A, et al. Adverse  
452 maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection:  
453 an individual participant data meta-analysis. *BMJ Global Health*. 2023;8(1):e009495.
- 454 12. Wilson SE, Deeks SL, Hatchette TF, Crowcroft NS. The role of seroepidemiology in  
455 the comprehensive surveillance of vaccine-preventable diseases. *Cmaj*. 2012;184(1):E70-E6.
- 456 13. Lai C-C, Wang J-H, Hsueh P-R. Population-based seroprevalence surveys of anti-  
457 SARS-CoV-2 antibody: An up-to-date review. *International Journal of Infectious Diseases*.  
458 2020;101:314-22.
- 459 14. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D, et al.  
460 High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of  
461 deaths in urban Malawi. *medrxiv*. 2020.
- 462 15. Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al.  
463 Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape  
464 Town, South Africa. *PLoS One*. 2021;16(2):e0247852.
- 465 16. Uyoga S, Adetifa IM, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al.  
466 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. *Science*.  
467 2021;371(6524):79-82.

- 468 17. WHO. Generic protocol: a prospective cohort study investigating maternal, pregnancy  
469 and neonatal outcomes for women and neonates infected with SARS-CoV-2. Geneva World  
470 Health Organisation 2020
- 471 18. WHO. WHO COVID-19 Case definition  
472 2020 [Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2)  
473 [Surveillance\\_Case\\_Definition-2020.2](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2)].
- 474 19. FIND DFA. FIND EVALUATION OF SARS-COV-2 ANTIBODY (AB)  
475 DETECTION TESTS 2021 [cited 2022 April 21st ]. Available from:  
476 <https://www.finddx.org/sarscov2-eval-antibody/>.
- 477 20. Edouard Mathieu HR, Lucas Rodés-Guirao, Cameron Appel, Daniel Gavrilov,  
478 Charlie Giattino, Joe Hasell, Bobbie Macdonald, Saloni Dattani, Diana Beltekian, Esteban  
479 Ortiz-Ospina, and Max Roser. Coronavirus Pandemic (COVID-19) 2023 [Available from:  
480 <https://ourworldindata.org/coronavirus#coronavirus-country-profiles>].
- 481 21. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection  
482 in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from  
483 January 2020 to December 2021. *BMJ Global Health*. 2022;7(8):e008793.
- 484 22. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:  
485 Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed  
486 SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020.  
487 *MMWR Morb Mortal Wkly Rep*. 2020;69(44):1641-7.
- 488 23. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are  
489 clinical outcomes worse for pregnant women at  $\geq 20$  weeks' gestation infected with  
490 coronavirus disease 2019? A multicenter case-control study with propensity score matching.  
491 *Am J Obstet Gynecol*. 2020;223(5):764-8.

- 492 24. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical  
493 manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019  
494 in pregnancy: living systematic review and meta-analysis. *Bmj*. 2020;370:m3320.
- 495 25. Budhram S, Vannevel V, Botha T, Chauke L, Bhoora S, Balie GM, et al. Maternal  
496 characteristics and pregnancy outcomes of hospitalized pregnant women with SARS-CoV-2  
497 infection in South Africa: An International Network of Obstetric Survey Systems-based  
498 cohort study. *Int J Gynaecol Obstet*. 2021;155(3):455-65.
- 499 26. De Waard L, Langenegger E, Erasmus K, Van der Merwe T, Olivier SE, Du Toit N,  
500 et al. Maternal and neonatal outcomes of COVID-19 in a high-risk pregnant cohort with and  
501 without HIV. *S Afr Med J*. 2021;111(12):1174-80.
- 502 27. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal  
503 and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-  
504 19 Infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatrics*.  
505 2021;175(8):817-26.
- 506 28. Nachega JB, Sam-Agudu NA, Machezano RN, Rosenthal PJ, Schell S, de Waard L, et  
507 al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Pregnancy in Sub-  
508 Saharan Africa: A 6-Country Retrospective Cohort Analysis. *Clinical Infectious Diseases*.  
509 2022;75(11):1950-61.
- 510 29. Rubio R, Aguilar R, Bustamante M, Muñoz E, Vázquez-Santiago M, Santano R, et al.  
511 Maternal and neonatal immune response to SARS-CoV-2, IgG transplacental transfer and  
512 cytokine profile. *Front Immunol*. 2022;13:999136.
- 513 30. Edlow AG, Li JZ, Collier A-rY, Atyeo C, James KE, Boatman AA, et al. Assessment of  
514 Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and  
515 Placental Pathology in Pregnancies During the COVID-19 Pandemic. *JAMA Network Open*.  
516 2020;3(12):e2030455-e.

- 517 31. Otter A. Personal Communication 2023
- 518 32. Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, et al.
- 519 Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the
- 520 Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
- 521 Ann Intern Med. 2022;175(9):1258-65.
- 522

## Supplementary Information

**S1 Fig. Placental transfer of anti-n IgG in A) PeriCOVID Uganda and B) COMAC Uganda.** Geometric mean ratios (GMRs) of anti-nucleocapsid IgG for each mother-infant pair with results available for analysis on the Euroimmune anti-nucleocapsid IgG assay. Boxplots of the GMRs show no evidence of a difference in placental transfer in different waves of the pandemic

**S2 Fig. Monthly number of positives in COMAC Uganda, by vaccination status** The monthly number of women in COMAC Uganda who were seropositive at enrolment on each of the Wantai (top panel), Euroimmune anti-S (middle panel) and Euroimmune anti-N (bottom panel) assays, coloured by vaccination status. Green shows those who were unvaccinated at enrolment, blue shows the small proportion who were vaccinated, and red shows those whose vaccination status was unknown at enrolment. The majority were unvaccinated.

523

524 **S1 Table. Wantai Assay Specificity.**

	Wantai positive (n)	Wantai negative (n)	Specificity (%)
2019 samples, malaria positive (n=74)	1	73	98.65
2019 samples, malaria negative (n=100)	1	99	99

525

526 **S2 Table. Dates used to define COVID-19 waves in Malawi and Uganda**

Country	Wave 1	Wave 2	Wave 3	Wave 4
Uganda	26/03/2020 – 21/03/2021	22/03/2021 – 30/11/2021	01/12/2021 – 30/04/2022	
Malawi	07/04/2020 – 16/11/2020	17/11/2020 – 15/05/2021	16/05/2021 – 11/11/2021	12/11/2021 – 20/04/2022

527

528

**S3 Table – Maternal PCR tests by study site and wave**

	PeriCOVID Malawi				PeriCOVID Uganda		
Characteristic	Overall, N = 73 (95% CI) <sup>12</sup>	Wave 2, N = 2 (95% CI) <sup>12</sup>	Wave 3, N = 31 (95% CI) <sup>12</sup>	Wave 4, N = 40 (95% CI) <sup>12</sup>	Overall, N = 836 (95% CI) <sup>12</sup>	Wave 1, N = 194 (95% CI) <sup>12</sup>	Wave 2, N = 642 (95% CI) <sup>12</sup>
PCR result							
Negative	24 (33%) (22%, 45%)	1 (50%) (1.3%, 99%)	11 (35%) (19%, 55%)	12 (30%) (17%, 47%)	817 (98%) (96%, 99%)	194 (100%) (98%, 100%)	623 (97%) (95%, 98%)
Positive	49 (67%) (55%, 78%)	1 (50%) (1.3%, 99%)	20 (65%) (45%, 81%)	28 (70%) (53%, 83%)	19 (2.3%) (1.4%, 3.5%)	0 (0%) (0.00%, 1.9%)	19 (3.0%) (1.8%, 4.6%)
Symptoms in those with positive PCR							
Asymptomatic	2 (4.1%) (0.50%, 14%)	0 (0%) (0.00%, 98%)	0 (0%) (0.00%, 17%)	2 (7.1%) (0.88%, 24%)	13 (68%) (43%, 87%)	NA	13 (68%) (43%, 87%)
Symptomatic	47 (96%) (86%, 100%)	1 (100%) (2.5%, 100%)	20 (100%) (83%, 100%)	26 (93%) (76%, 99%)	6 (32%) (13%, 57%)	NA	6 (32%) (13%, 57%)

529

Symptoms are those defined as probable infection according to WHO criteria (18)

530

531

532

533

534

535

536

537

**S4 Table – Adverse pregnancy outcomes in mothers enrolled in PeriCOVID Malawi and PeriCOVID Uganda**

Characteristic	All Enrolled	Wantai Overall	Wantai Serostatus	
	N = 1,224 <sup>1</sup>	N = 1,220 <sup>1</sup>	Negative, N = 469 <sup>2</sup>	Positive, N = 751 <sup>2</sup>
Maternal death	4 (0.3%)	4 (0.3%)	1 (25%)	3 (75%)
Unknown	27	25	9	16
Abortion	4 (0.3%)	4 (0.3%)	0 (0%)	4 (100%)
Unknown	25	24	9	15
Premature labour	52 (4.3%)	52 (4.3%)	20 (38%)	32 (62%)
Unknown	1			
Stillbirth	26 (2.1%)	26 (2.1%)	15 (58%)	11 (42%)
At least one adverse pregnancy outcome	79 (6.5%)	79 (6.5%)	34 (43%)	45 (57%)
No adverse pregnancy outcome	1,145 (94%)	1,141 (94%)	435 (38%)	706 (62%)
Livebirth	1,198 (98%)	1,194 (98%)	454 (38%)	740 (62%)

538

<sup>1</sup> Column percentages are presented for the overall number of women experiencing each outcome

539

<sup>2</sup> Row percentages are presented for the number of seropositive and seronegative women experiencing each outcome

540

541

542

543

544

545

546

547

**S5 Table - Adverse neonatal outcomes in infants born in PeriCOVID Malawi and PeriCOVID Uganda**

	<b>All infants</b>	<b>Wantai Overall</b>	<b>Maternal Wantai Serostatus</b>	
<b>Characteristic</b>	<b>N = 1,230<sup>1</sup></b>	<b>N = 1,227<sup>1</sup></b>	<b>Negative, N = 474<sup>2</sup></b>	<b>Positive, N = 753<sup>2</sup></b>
Infant death	46 (3.8%)	46 (3.8%)	20 (43%)	26 (57%)
Unknown	5	4	3	1
Prematurity	58 (4.7%)	58 (4.7%)	22 (38%)	36 (62%)
Unknown	1			
Low birth weight	61 (5.0%)	61 (5.0%)	22 (36%)	39 (64%)
Unknown	1			
Admitted to NICU	170 (14%)	170 (14%)	63 (37%)	107 (63%)
Unknown	4	3	3	0
Birth asphyxia	53 (4.3%)	53 (4.3%)	20 (38%)	33 (62%)
Unknown	1			
At least one adverse neonatal outcome	197 (16%)	197 (16%)	77 (39%)	120 (61%)
No adverse neonatal/infant outcome	1,033 (84%)	1,030 (84%)	397 (39%)	633 (61%)

548

<sup>1</sup> Column percentages are presented for the overall number of infants experiencing each outcome

549

<sup>2</sup> Row percentages are presented for the number of infants born to seropositive and seronegative women with each outcome

550



**S6 Table - Impact of infection (seropositive and WHO probable) on key pregnancy and neonatal outcomes**

	Number included in model	Number of events	Relative Risk	95% Confidence Interval
<b>Maternal death</b>				
Infection status		4		
sero-negative		1	—	—
sero-positive and not WHO probable		0	—	—
sero-positive and WHO probable		3	—	—
<b>Infant death</b>				
Infection status	1,223	46		
sero-negative	471	20	—	—
sero-positive and not WHO probable	667	24	0.85	0.47, 1.53
sero-positive and WHO probable	85	2	—	—
<b>Premature labour</b>				
Infection status	1,234	52		
Sero- negative	476	20	—	—
Sero- positive and not WHO probable	672	27	0.94	0.53, 1.67
Sero- positive and WHO probable	86	5	1.24	0.42, 3.00
<b>Still birth</b>				
Infection status	1,225	26		
Sero- negative	473	15	—	—
Sero- positive and not WHO probable	667	10	0.48	0.21, 1.05
Sero- positive and WHO probable	85	1	—	—
<b>Abortion</b>				
Infection status		4		
Sero- negative		0	—	—
Sero- positive and not WHO probable		4	—	—
Sero- positive and WHO probable		0	—	—

<b>Combined adverse pregnancy outcome</b>				
Infection status	1,205	79		
Sero- negative	463	34	—	—
Sero- positive and not WHO probable	659	36	0.74	0.47, 1.16
Sero- positive and WHO probable	83	9	1.39	0.64, 2.68
<b>Low birth weight</b>				
Infection status	1,227	61		
Sero- negative	474	22	—	—
Sero- positive and not WHO probable	668	33	0.99	0.59, 1.67
Sero- positive and WHO probable	85	6	0.98	0.37, 2.17
<b>NICU admission</b>				
Infection status	1,224	170		
Sero- negative	471	63	—	—
Sero- positive and not WHO probable	668	90	0.95	0.72, 1.28
Sero- positive and WHO probable	85	17	1.03	0.62, 1.60
<b>Combined adverse neonatal outcome</b>				
Infection status	1,234	197		
Sero- negative	476	77	—	—
Sero- positive and not WHO probable	672	102	0.91	0.70, 1.19
Sero- positive and WHO probable	86	18	0.98	0.60, 1.50

552 Models are adjusted for country

		PeriCOVID Uganda		COMAC Uganda	
		Wave 1	Wave 2	Wave 2	Wave 3
Anti-S	Infant, GMC (95% CI)	78.8 (46.4, 133.7) [N = 27]	127.6 (100.6, 161.8) [N = 181]	152 (100.3, 230.3) [N = 60]	65.2 (47.1, 90.4) [N = 59]
	Mother, GMC (95% CI)	51.7 (34.6, 77.3) [N = 27]	74.7 (59.3, 94.2) [N = 181]	96.1 (65.9, 140.1) [N = 60]	98.5 (68.6, 141.5) [N = 59]
	Placental transfer, GMR (95% CI)	1.5 (0.9, 2.5) [N = 27]	1.7 (1.3, 2.3) [N = 181]	1.6 (0.8, 3) [N = 60]	0.7 (0.4, 1) [N = 59]
Anti-N	Infant, GMC (95% CI)	57.1 (38, 85.8) [N = 39]	133.7 (106.5, 167.8) [N = 194]	155.9 (102.1, 237.9) [N = 55]	172 (103, 287.2) [N = 43]
	Mother, GMC (95% CI)	57.6 (41.5, 79.9) [N = 39]	146.2 (114.4, 186.8) [N = 194]	87.6 (54.9, 139.8) [N = 55]	62.9 (35.5, 111.4) [N = 43]
	Placental transfer, GMR (95% CI)	1 (0.6, 1.6) [N = 39]	0.9 (0.7, 1.3) [N = 194]	1.8 (1.1, 2.9) [N = 55]	2.7 (1.7, 4.4) [N = 43]




556

557

558

Figure 1 – Study flow chart



Study flow chart to show the number of women enrolled by study, with maternal serology available at enrolment (maternal result) and the infants with cord blood serology (cord blood result) available

Figure 2 – Monthly sero-positivity by country in pregnant women





Figure 2

Figure 3 – Placental transfer of anti-s IgG in A) PeriCOVID Uganda and B) COMAC Uganda




Geometric mean ratios (GMRs) of anti-spike IgG for each mother-infant pair with results available for analysis on the Euroimmune anti-spike IgG assay. Boxplots of the GMRs show no evidence of a difference in placental transfer in different waves of the pandemic.

Figure 3




Figure S1 – Placental transfer of anti-n IgG in A) PeriCOVID Uganda and B) COMAC Uganda



Geometric mean ratios (GMRs) of anti-nucleocapsid IgG for each mother-infant pair with results available for analysis on the Euroimmune anti-nucleocapsid IgG assay. Boxplots of the GMRs show no evidence of a difference in placental transfer in different waves of the pandemic

Figure S2 - Monthly number of positives in COMAC Uganda, by vaccination status



The monthly number of women in COMAC Uganda who were seropositive at enrolment on each of the Wantai (top panel), Euroimmune anti-S (middle panel) and Euroimmune anti-N (bottom panel) assays, coloured by vaccination status. Green shows those who were unvaccinated at enrolment, blue shows the small proportion who were vaccinated, and red shows those whose vaccination status was unknown at enrolment. The majority were unvaccinated.